Abstract |
Eighteen patients with symptomatic HIV disease were enrolled into a phase I/II study of a microsphere formulation of the HIV protease inhibitor KNI-272, with doses escalated up to a maximum dose of 60 mg/kg/day. One patient developed reversible elevation in hepatic transaminase. The plasma half-life of the drug was very short, varying between 0.25 and 1.1 h. No consistent effect on plasma HIV RNA levels or CD4(+) lymphocyte counts was seen.
|
Authors | D R Churchill, P M Slade, M Youle, B G Gazzard, J N Weber |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 47
Issue 3
Pg. 353-5
(Mar 2001)
ISSN: 0305-7453 [Print] England |
PMID | 11222570
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Anti-HIV Agents
- Oligopeptides
- RNA, Viral
- Alanine Transaminase
- kynostatin 272
|
Topics |
- Adult
- Alanine Transaminase
(drug effects, metabolism)
- Anti-HIV Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Area Under Curve
- CD4 Lymphocyte Count
- CD4-Positive T-Lymphocytes
(cytology, drug effects)
- Cohort Studies
- Dose-Response Relationship, Drug
- HIV Infections
(drug therapy)
- HIV-1
(drug effects, genetics)
- Humans
- Male
- Microspheres
- Middle Aged
- Oligopeptides
(adverse effects, pharmacokinetics, therapeutic use)
- Patient Dropouts
- RNA, Viral
(blood, drug effects)
- Treatment Outcome
|